Recovery article

AOD-9604 Peptide Cost in 2026: Pricing and Insurance Insights

Key Takeaways AOD-9604 is not FDA-approved and is available for research purposes only, affecting its cost and availability. Typical costs for AOD-9604 can vary widely based on brand and compounding options, with many patients paying out of pocket. Insurance c

By Recovery & Performance Peptides Editorial Team Published June 22, 2026

Key Takeaways

AOD-9604 is not FDA-approved and is available for research purposes only, affecting its cost and availability.

Typical costs for AOD-9604 can vary widely based on brand and compounding options, with many patients paying out of pocket.

Insurance coverage for AOD-9604 is rare, as it is not FDA-approved for therapeutic use.

HSA/FSA funds may not cover AOD-9604 due to its research-only status.

Cost-saving options include exploring compounding pharmacies (where legal) and discount programs.

What Is AOD-9604?

AOD-9604 is a growth hormone fragment peptide consisting of amino acids 177–191 of the human growth hormone sequence. It is primarily used in metabolic research and adipocyte differentiation studies. AOD-9604 operates by modulating lipid and glucose metabolism pathways through β-adrenergic and AMPK-related mechanisms. For more detailed information, visit the AOD-9604 full profile.

Typical Cost Ranges

AOD-9604 is not FDA-approved for therapeutic use and is available for research purposes only. As such, it is not legally available for therapeutic use in the United States, which significantly impacts cost information and availability. When available through research channels, costs can vary:

Brand-name medication: Typically unavailable due to its research-only status.

Compounded version: Prices can range from $50 to $150 per vial, depending on the compounding pharmacy and volume purchased.

Per-dose vs. monthly cost: Patients involved in research may see costs ranging from $100 to $300 monthly, depending on dosing frequency and concentration.

Due to its restricted status, most individuals involved in research pay out of pocket.

Insurance Coverage

Insurance coverage for AOD-9604 is virtually nonexistent due to its classification as a research-only substance. FDA-approved peptides are more likely to receive coverage, but AOD-9604 does not fall into this category. Patients involved in research should be prepared to cover costs independently, as compounded peptides are rarely covered.

HSA/FSA Eligibility

AOD-9604 does not typically qualify for HSA/FSA spending due to its status as a research peptide. These accounts usually cover FDA-approved treatments or those deemed medically necessary, which does not apply to AOD-9604.

Telehealth vs. In-Person Pricing

Telehealth clinics often bundle consultation and medication into monthly programs, which can offer convenience and potential cost savings for research participants. However, given the research-only status of AOD-9604, availability through telehealth services may be limited. In-person research settings may offer more consistent access.

Ways to Reduce Cost

Compounding pharmacies: In jurisdictions where legal, these can offer more affordable options.

Patient assistance programs: While rare for research peptides, some manufacturers may offer support.

Discount tools: Platforms like GoodRx may provide discounts for related medications, though applicability to AOD-9604 is limited.

Cost Compared to Alternatives

When comparing AOD-9604 to other peptides, such as CJC-1295 or Ipamorelin, it's important to note that these alternatives may have more established therapeutic uses and potentially more accessible pricing structures due to broader availability. However, each peptide's specific mechanism and research focus should guide selection.

What to Ask Your Provider About Cost

What are the total expected costs for participating in research involving AOD-9604?

Are there any legal compounding options available for AOD-9604?

Can you recommend any patient assistance programs or discount options?

How does the cost of AOD-9604 compare to other peptides you offer?

FAQ

Q: Is AOD-9604 covered by insurance? A: No, AOD-9604 is not covered by insurance as it is not FDA-approved for therapeutic use. It is available for research purposes only.

Q: Can I use HSA/FSA funds for AOD-9604? A: Typically, no. HSA/FSA funds generally cover FDA-approved treatments or those deemed medically necessary.

Q: How can I reduce the cost of AOD-9604? A: Explore legal compounding options, patient assistance programs, and discount tools, though options may be limited due to its research-only status.

Medical Disclaimer This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing in a Research Context

Because AOD-9604 is not an approved medicine, there is no established therapeutic dose, and the figures that circulate come from the historical trial protocols and from research-chemical convention rather than from any regulatory label. This section is descriptive and strictly educational, not a usage recommendation. The human efficacy trials used oral AOD-9604, with dose arms spanning roughly 0.25 mg to 30 mg once daily across the two studies.3 A striking and under-appreciated feature of the trial data is that the lower doses (around 1 mg) tended to perform at least as well as the higher ones — an inverted or flat dose-response that is unusual for a drug thought to act through a straightforward receptor-mediated pathway, and that in itself raises questions about how reliably the compound was doing what it was supposed to do. Oral peptide delivery is also notoriously inefficient, since the gut degrades peptides; the fact that development used an oral formulation complicates any attempt to reason from trial doses to the subcutaneous injection favored in contemporary research settings. In non-clinical and research-chemical contexts today, AOD-9604 is typically encountered as a lyophilized powder reconstituted for subcutaneous use, and the microgram-per-injection figures quoted by vendors (commonly a few hundred micrograms) bear no validated relationship to the oral milligram doses used in the actual efficacy trials. This is a crucial honesty point: no one has run a properly po…

Question drills

Open a question for its connected answer.

01Who is (and is not) a candidate for AOD-9604?+

If AOD-9604 works as intended, with a direct but relatively mild lipolytic action, then the ideal candidate is someone who wants to shed a moderate amount of weight. Compared to a GLP-1 receptor agonist, the high-speed rail of weight-loss drugs, AOD-9604 is like a Honda Super Cub: better for nearer destinations or longer-term journeys. That sort of approach would be particularly suited to anyone who’d rather avoid the loss of lean muscle mass that attends the calorie intake associated with GLP-1 peptides. Again, if it works as intended. The overall results of the Phase 2B clinical trial are reason enough to be guarded about expectations. If AOD-9604’s fat-loss effects are indeed more modest than initially believed, then any indicated candidate should view it with some measure of reservation. Then there are the contraindicated populations, for whom AOD-9604 isn’t an option at all, or at least a dubious one. These include but aren’t necessarily limited to: Pregnant or breastfeeding women: Safety data being sparse already, there certainly isn’t enough research to guarantee the safety of the developing fetus or child. People with an active cancer diagnosis or a history of cancer: Although AOD-9604 shouldn’t have the growth hormone effects of a typical HGH derivative, there’s still some concern about a theoretical risk of tumorigenesis. Current or surviving cancer patients should discuss with their doctor whether AOD-9604 is a viable treatment for them. Competitive athletes: As a growth hormone fragment, AOD-9604 is presently a non-approved substance on the World Anti-Doping Agency’s Prohibited List. 14 It can therefore trigger a positive drug test, disqualifying you from competition.

SOURCE / www.innerbody.com ↗

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Tissue and Cartilage Research

Some exploratory trials have studied the peptide’s potential role in: Cartilage regeneration Post-injury recovery Inflammation modulation However, these are preliminary and not validated for medical use.

Product & matchup locker

Linked catalog and comparison files.

Comparison

Claim by Claim: Animal Evidence vs Human Evidence

Every claim on a typical AOD 9604 sales page traces back to one of these rows. Stimulates lipolysis Yes, obese Zucker rats and ob/ob mice (Ng 2000; Heffernan 2001) Not measured as…